EN
HI

Alkem Laboratories Share price

ALKEM

HealthcareLarge

5098.5

196.00 (-3.70%)
NSE
BSE
Last updated on 30 May, 2025 | 15:55 IST
BUYSELL
Today's High

5268.00

Today's Low

5043.50

52 Week Low

4407.05

52 Week High

6439.90

The current prices are delayed, login to your account for live prices

Alkem Laboratories Chart

Alkem Laboratories Share Key Metrics

Volume
7.25 L
Market Cap
60960.22 CR
LTQ@LTP
1@5098.50
ATP
5101.29
Var Margin
13.4 %
Circuit Range
4765.5-5823.5
Delivery %
18.11 %
Value
369.76 CR
ASM/GSM
No
Market Lot
1

Alkem Laboratories Futures & Options

ALKEM-EQ

5098.5

-196 (-3.7%)

Alkem Laboratories Option Chain

View Price, OI, Greeks & More...
View Allee

26JUN25

49.80

-213.00 (4.10%)

31JUL25

49.34

-273.50 (5.25%)

28AUG25

49.60

4960.00 (Infinity%)

ALKEM|26JUN25 CE 5050.00

119.90

-255.6 (-68.07%)

ALKEM|26JUN25 PE 5100.00

231.65

114.7 (98.08%)

Alkem Laboratories Corporate Actions

DateAgenda
2025-05-29Audited Results & Final Dividend
2025-02-14-
2025-02-07Quarterly Results & Interim Dividend
DateEvent TypeAgenda
2025-05-29Board MeetingAudited Results & Final Dividend
2025-02-14Dividend-
2025-02-07Board MeetingQuarterly Results & Interim Dividend

Alkem Laboratories News

Cipla, Alkem Laboratories in final lap to buy SMT

Oct 16 2024 05:32:05

Cipla, Alkem Laboratories in final lap to buy SMT

Oct 16 2024 05:32:00
Read More

About Alkem Laboratories

NSE : 11703  
BSE : 539523  
ISIN : INE540L01014  

The Company was incorporated as a private limited company ?Alkem Laboratories Private Limited? on August 81973 at Patna under the Companies Act 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act 1956 on October 26 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21 2001 the name of the Company was changed to ?Alkem Laboratories Limited? with effect from October 26 1988. the registered office was originally located at ?Exhibition Road Patna ? 800 001 Bihar India?. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra as approved by a special resolution at its extra-ordinary general meeting held on January 29 2007. The Company Law Board Eastern Region Bench at Kolkata passed an order dated July 30 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association from the State of Bihar to the State of Maharashtra. Pursuant to the order the registered office of the Company was shifted to ?Alkem House Senapati Bapat Marg Lower Parel Mumbai ? 400 013 Maharashtra India? with effect from August 2 2007.Major Events :1973-Incorporation of the Company. 1978-the Company established its first plant at Taloja Maharashtra. 1988-the Company became a deemed public limited company. 1992-the Company established its manufacturing facility in Mandwa Maharashtra. This facility was converted into an API facility in 2005. 1998-the Company established its Kachigam manufacturing facility in Gujarat. 2001-Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002-the Company established its Amaliya manufacturing facility in Gujarat. 2003-the Company set up its research and development facility at Taloja Maharashtra. 2005-the Company established its manufacturing facility in Baddi Himachal Pradesh. 2006-the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1000 million in terms of domestic sales in India (Source: IMS Research) 2007-the Company established its manufacturing facility in Kumrek Sikkim. -the Company filed its first ANDA in the United States for the drug Amlodipine. -the Company shifted its Registered Office from Patna Bihar to Mumbai Maharashtra. 2009-the Company acquired Pharmacor a generic pharma company in Australia. 2010-the Company acquired The PharmaNetwork LLC the holding company of Ascend Laboratories LLC. 2011-the Company acquired Enzene Bio sciences Limited. 2012-the Company acquired an API manufacturing facility in the United States. 2014-the Company acquired the Clindac. 2015-the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002-the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India?s Most Esteemed Pharmaceutical Company'2004-the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005-the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009-the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India supported by Ministry of Commerce and Industry GOI -the Company received the certificate of appreciation in the category of ?Formulation Experts? by the Pharmaceuticals Export Promotion Council of India supported by Ministry of Commerce and Industry GOI 2013-the Company was awarded the India?s most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014-the Product ?Clavam? was awarded as the ? Brand of the Year? at the AWACS Award 2014

Alkem Laboratories Management

NamePosition
Mr. Basudeo N Singh Executive Chairman
Mr. Sandeep Singh Managing Director
Mrs. Madhurima Singh Executive Director
Mr. Srinivas Singh Executive Director
Mr. Mritunjay Kumar Singh Executive Director
Read More

Alkem Laboratories FAQs

The Buying Price of Alkem Laboratories share is 5098.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Alkem Laboratories share log in to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of Alkem Laboratories shares is 28.14. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Alkem Laboratories shares is 5.08. Useful to assess the stock's value relative to its book value.

To assess Alkem Laboratories’s valuation compare Sector P/E, P/B which are 37.05 & 4.02 with sector averages, along with growth rates and financial metrics.

The Market Cap of Alkem Laboratories is 60960.22 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Alkem Laboratories share price is 6439.90 & 4407.05. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.